Sionna Therapeutics (NASDAQ:SION) Shares Up 4.5% – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION) shot up 4.5% during mid-day trading on Tuesday . The company traded as high as $12.91 and last traded at $12.65. 11,004 shares traded hands during trading, a decline of 95% from the average session volume of 231,585 shares. The stock had previously closed at $12.10.

Analysts Set New Price Targets

SION has been the subject of several research analyst reports. Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 price objective for the company. TD Cowen started coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating on the stock. Finally, Stifel Nicolaus began coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $32.00 target price on the stock.

Sionna Therapeutics Stock Up 5.0 %

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, March 20th. The company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.68) by ($0.70).

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.